Clinical Observation After Intravitreal Injection Of Conbercept In Age-related Macular Degeneration

Objective: To observe and analyze the safety and efficacy of intravitreal conbercept for wet Age-Related Macular Degeneration.Methods: It is a case control study before and after clinical treatment.The diagnosed exudative age related macular degeneration(AMD)patients totally 30 cases(30 eyes)who were treated with conbercept on a monthly treatment regimen from March 2015 to January 2016 at First Hospital of Dalian Medical University were included in the study.All of the patients received intravitreal conbercept(0.05ml/0.5mg),once a month for three months.The changes of BCVA and CMT were recorded during follow-up period.SPSS17.0 was used to analysis the dates.Probability less than 0.05 was considered to be statistically significant.Results: Thirty patients were included in the study,14(14eyes)of males and 16(16 eyes)of females,whose age were from 50 to 85 years old.The average age was 63.3±10.54 years old.The median BCVA(LogMAR)improved from 0.94±0.42 to 0.65±0.38(P=0.000)after 3 months.The median CMT decreased from(512.93±192.15)?m to(327.63±150.84)?m(P=0.000)after 3 months.The central retinal thickness was reduced.The median BCVA(LogMAR)improved from 0.94±0.42 to 0.76±0.29(P=0.000)and the CMT decreased from(512.93±192.15)?m to(427.03±162.15)?m(P=0.000)which compared the baseline with the first day after the treatment.The median BCVA(LogMAR)improved from 0.94±0.42 to 0.78±0.42(P=0.000)and the CMT decreased from(512.93±192.15)?m to(383.20±166.70)?m(P=0.001)compared the baseline with one month after the treatment.The median BCVA(LogMAR)improved from 0.94±0.42 to 0.72±0.40(P=0.000)and the median CMT decreased from(512.93±192.15)?m to(355.83±155.51)?m(P=0.000)compared the baseline with two months.The median BCVA(LogMAR)improved from 0.94±0.42 to 0.65±0.38(P=0.000)and the CMT decreased from(512.93±192.15)?m to(327.63±150.84)?m(P=0.000)which compared the baseline after three months.The median BCVA were 0.76±0.29 and 0.78±0.42(P=0.643)and the CMT were(427.03±162.15)?m and(383.20±166.70)?m(P=0.235)compared the first day after the treatment with one month after the treatment;The BCVA were 0.78±0.42 and 0.72±0.40(P=0.44)and the CMT were(383.20±166.70)?m and(355.83±155.51)?m(P=0.17)compared one month with two months after the treatment;The BCVA were 0.72±0.40 and 0.65±0.38(P=0.09)and the CMT were(355.83±155.51)?m and(327.63±150.84)?m(P=0.06)compared two months with three months after the treatment.No ocular and systemic complications occurred during three months follow up period.Conclusion: 1?Intravitreal injection of 0.05ml/0.5mg Conbercept is safe and effective for wet age-related macular degeneration in short term and no obvious side effects were found;2?OCT could be guided by CMT value change,which was convenient for clinical observation.The long-term effect was still need to evaluate the multi center,large sample,randomized study.